- Home
- ABVC vs CBUS Comparison
ABVC vs CBUS Comparison
Compare ABVC & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | CBUS |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 69.9M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ABVC | CBUS |
|---|---|---|
| Price | $2.27 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 82.1K | ★ 208.0K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $797,916.00 | ★ $3,794,000.00 |
| Revenue This Year | $735.18 | N/A |
| Revenue Next Year | N/A | $109.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.52 | N/A |
| 52 Week Low | $0.40 | $1.09 |
| 52 Week High | $5.48 | $3.40 |
Technical Indicators
Market Signals| Indicator | ABVC | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 77.93 |
| Support Level | $2.05 | $1.59 |
| Resistance Level | $2.43 | $1.80 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 58.51 | 96.74 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.